Literature DB >> 21390516

Reversible posterior leukoencephalopathy induced by carboplatin and etoposide.

S A Ryan1, P Maceneaney, S P O'Reilly, E J Moylan, D G Power.   

Abstract

Reversible posterior leukoencephalopathy syndrome (RPLS) is a rare neurologic condition characterised by specific clinical and radiologic findings. It usually manifests subacutely as insidious onset of headache, visual disturbance, altered consciousness and seizures in association with MRI findings of posterior white matter vasogenic oedema. RPLS has been reported in a wide variety of clinical settings. Hypertension, eclampsia, pre-eclampsia, renal impairment, autoimmune conditions and cytotoxic drugs are all cited as aetiologic variables. RPLS, albeit rare, is an important entity for physicians to be aware of as early recognition, and prompt intervention is critical to ensure resolution of the neurological deficit. We describe the case of a 69-year-old lady who collapsed with seizure activity after receiving carboplatin and etoposide chemotherapy for small cell lung cancer. In our opinion, the clinical and radiological courses are typical of RPLS. RPLS has rarely been reported secondary to this chemotherapy regimen, and the purpose of this report is to add to the literature and highlight the association between RPLS and cytotoxic chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21390516     DOI: 10.1007/s12032-011-9898-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

Review 1.  Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed.

Authors:  V L Stott; M A Hurrell; T J Anderson
Journal:  Intern Med J       Date:  2005-02       Impact factor: 2.048

2.  Osteonecrosis of the jaw and bisphosphonates.

Authors:  Brian G M Durie; Michael Katz; John Crowley
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

3.  Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.

Authors:  Rangaswamy Govindarajan; Josna Adusumilli; Donna L Baxter; Anthony El-Khoueiry; Sami I Harik
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

4.  Chemotherapy induced reversible posterior leukoencephalopathy syndrome.

Authors:  Roisin M Connolly; Colin P Doherty; Peter Beddy; Ken O'Byrne
Journal:  Lung Cancer       Date:  2007-02-20       Impact factor: 5.705

Review 5.  Reversible posterior leukoencephalopathy syndrome in cancer.

Authors:  Christopher Vaughn; Louann Zhang; David Schiff
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

6.  A reversible posterior leukoencephalopathy syndrome.

Authors:  R B Schwartz
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

7.  The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance.

Authors:  A Benigni; M Morigi; N Perico; C Zoja; C S Amuchastegui; A Piccinelli; R Donadelli; G Remuzzi
Journal:  Transplantation       Date:  1992-11       Impact factor: 4.939

8.  Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study.

Authors:  L Edvinsson; C Owman; N O Sjöberg
Journal:  Brain Res       Date:  1976-10-22       Impact factor: 3.252

9.  Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

Authors:  Hans Lindå; Anders von Heijne; Eugene O Major; Caroline Ryschkewitsch; Johan Berg; Tomas Olsson; Claes Martin
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

10.  Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images.

Authors:  Diego J Covarrubias; Patrick H Luetmer; Norbert G Campeau
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

View more
  3 in total

Review 1.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398

2.  Posterior Reversible Encephalopathy Syndrome Following Chemotherapy and Immune Checkpoint Inhibitor Combination in a Patient with Small-Cell Lung Cancer.

Authors:  Cécile Evin; Nathalie Lassau; Corinne Balleyguier; Tarek Assi; Samy Ammari
Journal:  Diagnostics (Basel)       Date:  2022-06-02

3.  Chemoradiation induced multiple sclerosis-like demyelination.

Authors:  Alexandra Borges; Daniela Garcez; Cátia Pedro; João Passos
Journal:  eNeurologicalSci       Date:  2021-01-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.